Perspective Therapeutics, Inc. · AMEX:CATX
Perspective Therapeutics — ESMO 2026
25 slides from Perspective Therapeutics's conference presentation, Oct 23, 2026
Slide 1: Investor Call: ESMO 2026 Presentation
PERSPECTiVE’ THERAPEUTICS Investor Call ESMO 2026 Presentation Bamzireotide navoxetan : Phase 1/2a data update (?2Pb VMT-a-NET) NYSE AMERICAN: CATX
Slide 2: Legal Disclaimers
Legal Disclaimers This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words such as “may,” “will,” “s
Slide 3: Next Opportunity is for Deeper and More Durable Disease Control
INVESTOR CONTEXT | GEP-NET Next Opportunity is for Deeper and More Durable Disease Control WHERE PATIENTS ARE TODAY 1L SSA backbone Octreotide / lanreotide GY rossess0n Post-SSA options Lutathera ¢ Everolimus + Sunitinib (pNET) * Cabozantinib « non-approved (e.g. CAPTEM) Treatment selection and sequ
Slide 4: SSTR2+ GEP-NETs: Compelling Data Addressing a Significant Unmet Need
NEUROENDOCRINE TUMORS SSTR2+ GEP-NETs: Compelling Data Addressing a Significant Unmet Need ~~ 2 50 K | ~~ 1 2 K 90% © Room for a Next-Generation Alpha RLT 212; in oe People living with NETs in the U.S.2 of GEP-NETs express SSTR2> ¢ Pb alpha payload: high-energy, And newly diagnosed annual in the U.S
Slide 5: Ongoing Phase 1/2a to Establish Broad Therapeutic Window for Bamzireotide Navoxetan
Ongoing Phase 1/2a to Establish Broad Therapeutic Window for Bamzireotide Navoxetan
Slide 6: ESMO 2026 Analysis: Compelling Profile Across Doses
ESMO 2026 DATA ESMO 2026 Analysis: Compelling Profile Across Doses Va \ Best overall response by cohort Time on study and response Safety Overview Cohort 1 | Cohort Cohort 3 Cohort 2 Cohort 3 ES 6 (%) | n=20 (4) Safety Analysis Set 46 (%) | n=20 (%) 5 ‘Subjects with >1 TEAE 20 (100) Disease control
Slide 7: ESMO 2026 Analysis: Compelling Profile Across Doses
ESMO 2026 DATA ESMO 2026 Analysis: Compelling Profile Across Doses 7 Kaplan-Meier estimate of PFS ») { Landmark PFS rate, % (95% Cl) Cohort 1 Cohort 2 Cohort 3 Coho! 10 (N=2) (N=46) (N=20) (N= oF 6 months 82.6 (68.2-90.9) 89.1 (62.7-97.2) 85.7 (74.9-92.0) 08 Bor 12 months 100 71.2 (55.7-82.2) 76.3 (
Slide 8: Higher Responses Observed in Cohort 3 Relative to Cohort 2
ESMO 2026 DATA Higher Responses Observed in Cohort 3 Relative to Cohort 2 at Early Assessments ORR and disease control by cohort, ITT (%) 95% Cohort 2 - 5.0 mCix 4 (n=46) Cohort 3 - 6.0 mCi x 4 (n=20) M Objective response rate ™ Disease control rate ‘*Represents DCO 10 Sep 2026 (includes 2 PRs after
Slide 9: Safety Profile Remains Favorable
ESMO 2026 DATA Safety Profile Remains Favorable Most common TEAEs (215%), % of patients Alopecia Nausea Fatigue Diarrhoea Abdominal pain Lymphocyte count decreased Hypertension Constipation Back pain Anaemia 20% 40% Grade 3 mGrade2 mGrade1 Safety analysis set: Cohorts 1-3 (N = 68) 000000 No DLTs No
Slide 10: Continued Favorable Renal Profile
ESMO 2026 DATA Continued Favorable Renal Profile Renal Safety Profile 2 patients with Grade 3 AEs (2.9%) Both acute kidney injury 1 unlikely related, 1 possibly related, by investigator assessment 1 resolved, 1 ongoing Creatinine (mg/dL) -10 0 10 20 30 40 50 60 70 80 90 100 110 120 130 140 Weeks aft
Slide 11: Upcoming Milestones and Financial Position
MILESTONES Upcoming Milestones and Financial Position Program Bamzireotide navoxetan (VMT-a-NET) SSTR2 - NETs Lapemelanotide zapixetan (vmT01) MC1R - melanoma PSV359 FAP-a-- solid tumors PSsv594 CCK2R - solid tumors 11) Late 2026 NANETS 2026 data; EMA protocol assistance; >18 and >24-month Cohort 2
Slide 12: Q&A
my PERSPECTIVE’ THERAPEUTICS Q&A NYSE AMERICAN: CATX
Slide 13: Appendix
my PERSPECTIVE’ THERAPEUTICS Appendix
Slide 14: Radioligand Therapy Trials in SSTR2+ GEP-NETs
APPENDIX Radioligand Therapy Trials in SSTR2+ GEP-NETs 7Lu-DOTATATE NETTER-1',? - Randomized 2:1 vs high- ‘7Lu-edotreotide ‘COMPETE® - Randomized 2:1 vs 22Pb-DOTAMTATE ™5Ac-DOTATATE ™Pb-bamzireotide navoxetan = x ACTION-1 Phase Ib*- Single arm - 5 = study pe pT coma eae Phase II” - Single arm - N=35
Slide 15: U.S. Second-Line GEP-NET Use Trending towards PRRT and Targeted Therapy
ae REAL-WORLD TREATMENT PATTERNS U.S. Second-Line GEP-NET Use Trending towards PRRT and Targeted Therapy Treatment class Therapies in class* PRRT Lutetium Lu-177 (LUTATHERA®) Targeted therapy Everolimus, cabozantinib, sunitinib Unapproved / other* Cytotoxic and other / combination regimens eal towar
Slide 16: Abbreviations
APPENDIX Abbreviations AE: adverse event BICR: blinded independent central review BOIN12: Bayesian optimal interval Phase I/II CAPTEM: capecitabine + temozolomide CHMP: Committee for Medicinal Products for Human Use Cl: confidence interval CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration C
Slide 17: ESMO 2026
my PERSPECTIVE’ THERAPEUTICS ESMO 2026
Slide 18: Authors and Affiliations
Thorvardur Halfdanarson’, Vikas Prasad?, Vineeth Sukrithan®, Brandon Mancini*, Seyed Mosallaie*, Savitha Balaraman®, Gregory Sibley’, Jason Starr®, Lowell Anthony®, Chih-Yi Liao*®, Samuel Mehr"’, Jared Weiss’?, Robert Ramirez**, Amir Iravani"*, Lucia Baratto’®, Shilpen Patel’®, Markus Puhlmann’®, Ri
Slide 19: Declaration of Interests
Declaration of Interests Research support to institution: Thermo Fisher Scientific, Advanced Accelerator Applications (a Novartis company), Camurus, Crinetics, ITM Isotope Technologies Munich, RayzeBio (a Bristol Myers Squibb company), Perspective Therapeutics, Rezolute, Exelixis Consulting/Advisory
Slide 20: Study Design and Baseline Characteristics
Study Design and Baseline Characteristics Design: Phase 1/2a dose escalation and exploration in PRRT-naive, SSTR2-positive NETs Doses: Cohort 1, 2.5 mCi; Cohort 2, 5.0 mCi; Cohort 3,* 6.0 mCi (x 4 doses every 8 weeks) Primary endpoints: Safety, DLTs, and ORR. Secondary endpoints: PFS (Investigator-a
Slide 21: Safety: Overall Profile TEAE
Safety: Overall Profile TEAE = Cohort 1 Cohort 2 Cohort 3 Total SELAH GUC OG N=2 (% N=46 (% N=20 (% N=68 (% Subjects with 21 TEAE 2 (100) 45 (97.8) 20 (100) 67 (98.5) Alopecia 2 (100) 32 (69.6) 12 (60.0) 46 (67.6) Fatigue 2 (100) 30 (65.2) 12 (60.0) 44 (64.7) Nausea 1 (50.0) 26 (56.5) 18 (90.0) 45 (
Slide 22: Efficacy
Efficacy Objective Responses in Cohort 2 (33%) and Cohort 3 (40%"*), with disease control in 289% of patients in each cohort ¥ Best overall response by cohort ORR cep.NeT SSTR2+ (0.0) (36.8) (5.3) Disease control = CR/PR/SD. *Two additional uPRs reported as of 10 Sep 2026, fora total of 5 uPRs and a
Slide 23: PFS
PFS Kaplan-Meier estimate of PFS e © & — Cohort 1 (N=2) — Cohort 2 (N=46) 0.34 —~ Cohort 3 (N=20) Survival Probability £ & 02 2 2 2 2 2 hn 01146 40 33 23 6 | tek 00120 16 7 0 0 5 10 15 20 Time from Treatment Start (Months) Curves are truncated at 20 months, where few patients remain at risk (Cohort
Slide 24: Durability of response was observed across all cohorts
Durability urable | was observed across all cohorts (7 Time on study and response > (Cohort 3: Percent change from baseline in target lesions over time ™ 50 ® Additional unconfirmed PR as of 10 Sep 2026 z | oS id i 2 i i S| = = 8 2 Study Week Dose Level ™ Cohort 3 Investigator-assessed RECIST v1.1.
Slide 25: Conclusions and Next Steps
Conclusions and Next Steps SAFETY EFFICACY Cohort 2: No Dysphagia + DCR 89% No DLTs + ORR 33% No Myelodysplastic Syndrome + PFS at 18 months 69% Cohort 3: Long-term safety follow-up is ongoing + DCR 95% + ORR 40% (50% as of 10 Sep 2026) + PFS at 12 months 76% s in the VMT-a-NET-T101 trial = Copies o